Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 8/20 | 0.52 |
| ▸ | CA12 | O43570 | 5/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | CA9 | Q16790 | 5/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | MMP8 | P22894 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | MMP1 | P03956 | 3/20 | 0.51 |
| ▸ | MMP3 | P08254 | 3/20 | 0.51 |
| ▸ | MMP7 | P09237 | 3/20 | 0.51 |
| ▸ | MMP9 | P14780 | 3/20 | 0.51 |
| ▸ | MMP13 | P45452 | 3/20 | 0.51 |
| ▸ | MMP14 | P50281 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7413588 | 0.83 | MMP2 (0.66) | MMP2CA12CA2CA9CA1 | |
| SCHEMBL7413590 | 0.83 | MMP2 (0.66) | MMP2CA12CA2CA9CA1 | |
| SCHEMBL7651281 | 0.70 | MMP2 (0.66) | MMP2CA12CA2CA9CA1 | |
| SCHEMBL7375064 | 0.70 | MMP2 (0.66) | MMP2CA12CA2CA9CA1 | |
| SCHEMBL14602254 | 0.70 | MMP2 (0.67) | MMP2MMP1MMP3MMP7MMP9 | |
| SCHEMBL1287270 | 0.70 | MAPT (0.57) | MAPTALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL1287300 | 0.70 | MAPT (0.57) | MAPTALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL7409478 | 0.70 | MMP2 (0.74) | MMP2CA12CA2CA9CA1 | |
| SCHEMBL7409476 | 0.70 | MMP2 (0.74) | MMP2CA12CA2CA9CA1 | |
| SCHEMBL31124612 | 0.69 | MMP2 (0.58) | MMP2CA12CA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082246-A1 | Sulfonylaminophosphinic and sulfonylaminophosphonic acid derivatives, methods for their preparation and use | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2002-06-27 | — | — | US | claimed |
| US-6235727-B1 | ENZYME INHIBITORS; MUSCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082246-A1 | Sulfonylaminophosphinic and sulfonylaminophosphonic acid derivatives, methods for their preparation and use | ARSA, STS, PNPO | MMP2 24/4885CA12 1117/4885CA2 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.